Key Takeaway: Benitec Biopharma announced an upcoming update on its Phase 1b/2a clinical study of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). The update will cover six patients from the initial cohort. The webcast is scheduled for November 3, 2025, at 8:00 am EST, reflecting the company's commitment to transparency in its clinical trials.
Price reaction · baseline $16.36 (2025-10-31 close) · 4 other BNTC headline(s) in the window, move may be shared
day 0 close
-3.1%
day 1
-4%
day 3 · peak
-26.7%
Market Sentiment Analysis
POSITIVE FACTORS
Benitec Biopharma is advancing its innovative gene therapy platform.
The update on the Phase 1b/2a study indicates progress in treating OPMD.
The company is focused on developing solutions for serious health conditions.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
8.7%
average across 3 past catalysts
Cash runway
~38 mo
Minimal dilution risk
Lead asset
BB-401
Phase 2 · Head and Neck Squamous Cell Carcinoma
Full Press Release Details
HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced that it will provide an update on the six treated patients from Cohort 1 of its Phase 1b/2a Clinical Study of BB-301 being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).
Webcast details:Date:November 3, 2025Time:8:00 am ESTTo register for the webcast, please clickhere.
AboutBenitecBiopharmaInc.Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website atwww.benitec.com.